SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for DIGIRAD CORP (STRR, STRRP) (CIK 0000707388) — May 8, 2020

DIGIRAD CORP (STRR, STRRP) (CIK 0000707388)
Date: May 8, 2020 · CIK: 0000707388 · Accession: 0000000000-20-004043

AI Filing Summary & Sentiment

File numbers found in text: 333-237928

Date
May 7, 2020
Author
Not clearly detected
Form
UPLOAD
Company
DIGIRAD CORP (STRR, STRRP) (CIK 0000707388)

Letter

United States securities and exchange commission logo May 7, 2020 Matthew G. Molchan Chief Executive Officer Digirad Corporation 1048 Industrial Court Suwanee, Georgia 30024 Re:Digirad Corporation Registration Statement on Form S-1 Filed April 30, 2020 File No. 333-237928 Dear Mr. Molchan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason Cabico, Esq.

Show Raw Text
United States securities and exchange commission logo
May 7, 2020
Matthew G. Molchan
Chief Executive Officer
Digirad Corporation
1048 Industrial Court
Suwanee, Georgia 30024
Re:Digirad Corporation
Registration Statement on Form S-1
Filed April 30, 2020
File No. 333-237928
Dear Mr. Molchan:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jason Cabico, Esq.